A. Perez

Impact of total body irradiation based myeloablative conditioning regimen in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant: systematic review and meta-analysis.

J. Pidala, A. Mishra, L. Ochoa, 2021, Transplantation and cellular therapy.

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

E. Hoster, L. Bullinger, A. Mackensen, 2022, Journal for ImmunoTherapy of Cancer.

Therapeutic Challenges in Chronic Myeloid Leukemia: A Case-Based Discussion

Y. Galili, A. Perez, Grant Jester, 2020, Journal of medical cases.

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL

F. Locke, J. Chavez, B. Shah, 2022, Blood advances.

Outcomes of CD19 CAR T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma.

F. Locke, J. Chavez, B. Shah, 2021, Transplantation and cellular therapy.

Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis.

F. Locke, J. Chavez, B. Shah, 2022, Transplantation and cellular therapy.

Unusual Presentation of Lung Adenocarcinoma With Paraneoplastic Stiff Person Syndrome: Role of EGFR Tyrosine Kinase Inhibitors.

N. Avgeropoulos, Y. Galili, A. Perez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

F. Locke, A. Petrera, M. Subklewe, 2023, Science advances.

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

J. Pidala, A. Mishra, Jongphil Kim, 2022 .

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

E. Hoster, A. Mackensen, U. Holtick, 2023, HemaSphere.